A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma
This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new